Highlights SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
1.46 ^USD	-3.95%		-5.19%	+37.74%

Apr. 03	North American Morning Briefing : Powell Awaited -2-	DJ
Mar. 28	SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML	Mar. 26	CI
SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients	Jan. 09	CI
Exchange-Traded Funds, Equity Futures Mixed Pre-Bell Thursday as Traders Mull Fed Meeting Minutes	Jan. 04	MT
SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma	Dec. 27	CI
SELLAS Life Sciences Seeks Arbitration in Dispute with 3D Medicines	Dec. 27	MT
Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia	Dec. 14	CI
Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia	Dec. 04	CI
SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia	Nov. 29	CI
SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S	Nov. 13	CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting	Nov. 06	CI
SELLAS Gets FDA's Fast-Track Label for Treatment of Peripheral T-Cell Lymphomas	23-10-30	MT
SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia	23-10-16	CI
SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia	23-10-13	CI
SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 in Relapsed/Refractory Peripheral T-cell Lymphomas	23-10-11	CI
SELLAS Life Sciences Gets FDA Orphan Drug Designation for Acute Myeloid Leukemia Treatment; Shares Jump After Hours	23-10-10	MT
Sellas Life Sciences Group Gets FDA Orphan Drug Designation to Treat Type of Leukemia	23-10-10	DJ
SELLAS Life Sciences Group, Inc. Announces Positive Topline Data in Lymphoma Cohort from Sls009 Phase 1 Dose-Escalation Trial, Supporting Advancement to Phase 2 Clinical Study; Primary and Secondary Endpoints Met	23-09-21	CI
SELLAS Life Sciences Group, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights SELLAS Life Sciences Group, Inc.

Equities

SLS

US81642T2096

Highlights

Filters